公开(公告)号：WO2019081714A1

公开(公告)日：2019-05-02

申请号：PCT/EP2018/079425

申请日：2018-10-26

Applicant: VIB VZW ,  KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D

Inventor： MAZZONE, Massimiliano ,  BIENIASZ-KRZYWIEC, Pawel

IPC: G01N33/50 ,  A61K39/00 ,  G01N33/574

CPC classification number: G01N33/5055 ,  G01N33/5011 ,  G01N33/57492 ,  G01N2800/56

Abstract: The invention relates to the field of tumor metastasis and peritumoral lymphangiogenesis. More specifically, podoplanin present on a subset of tumor-associated macrophages was identified as target for treating or inhibiting tumor metastasis and peritumoral lymphangiogenesis, and podoplanin-positive macrophages were identified as biomarker for lymphatic metastasis. The invention further relates to screening methods for identifying compounds capable of neutralizing podoplanin-positive macrophages, and to methods and kits for tumor analysis or for lymph vessel analysis.

公开(公告)号：WO2018149978A1

公开(公告)日：2018-08-23

申请号：PCT/EP2018/053913

申请日：2018-02-16

Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Inventor： PEARCE, Erika ,  PULESTON, Daniel

IPC: G01N33/50

CPC classification number: G01N33/5055 ,  G01N33/5073

Abstract: The present invention relates to a method for determining whether a compound has the capability of inhibiting elF5a activation, comprising (a) contacting a sample comprising cells being capable of differentiating into M2 macrophages with the compound under conditions that allow for the differentiation of cells into M2-type macrophages in the absence of the compound; and (b) quantifying in the sample the cells having a M2-phenotype, wherein a reduction of the number of cells having a M2-phenotype as compared to a control sample not contacted with the compound indicates that the compound has the capability of inhibiting elF5a activation.

公开(公告)号：WO2016023006A1

公开(公告)日：2016-02-11

申请号：PCT/US2015/044372

申请日：2015-08-07

Applicant: ALLEGHENY-SINGER RESEARCH INSTITUTE

Inventor： AHEARN, Joseph, M. ,  LIU, Chau-Ching ,  MANZI, Susan, M.

IPC: G01N33/564

CPC classification number: G01N33/564 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/5055 ,  G01N33/536 ,  G01N33/6854 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2800/104 ,  G01N2800/7095

Abstract: Provided are methods, systems, and kits for diagnosing or monitoring systemic lupus erythematosus in an individual. In particular aspects, in a blood sample containing white blood cells from the individual, autoantibodies deposited on or contacting with the surface of a T lymphocyte in the sample are quantitated.

Abstract translation: 提供用于诊断或监测个体系统性红斑狼疮的方法，系统和试剂盒。 在特定方面，在含有来自个体的白细胞的血液样品中，定量沉积在样品中的T淋巴细胞表面上或与其接触的自身抗体。

公开(公告)号：WO2015187295A2

公开(公告)日：2015-12-10

申请号：PCT/US2015029523

申请日：2015-05-06

Applicant: ARMO BIOSCIENCES INC

Inventor： MUMM JOHN BRIAN ,  CHAN IVAN HO

IPC: A61K49/00 ,  G01N33/53

CPC classification number: A61K39/385 ,  A61K38/00 ,  A61K38/1796 ,  A61K38/2066 ,  A61K47/60 ,  A61K48/00 ,  A61K49/0008 ,  C07K14/4705 ,  C07K14/4718 ,  C07K14/715 ,  C07K17/02 ,  C12Q1/60 ,  G01N33/5055 ,  G01N33/92

Abstract: Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating Kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an IL-10 agent are also provided.

Abstract translation: 提供了治疗患有疾病，病症或病症的受试者的方法，包括与胆固醇体内平衡相关的疾病，对调节枯否氏细胞功能的药剂的反应，包括给药方法和与其相关的给药方案。 还提供了利用IL-10剂治疗患有肝脏疾病，病症或病症，包括非酒精性脂肪性肝炎和非酒精性脂肪肝疾病的受试者的方法。

公开(公告)号：WO2015094985A3

公开(公告)日：2015-09-24

申请号：PCT/US2014070141

申请日：2014-12-12

Applicant: LO AMY HUIMEEI

Inventor： LO AMY HUIMEEI ,  LIN YONG CHI ,  LIN PO WEN ,  LIN PO YU ,  LIN JING MEEI

IPC: A01N65/00

CPC classification number: G01N33/5047 ,  A61K36/73 ,  C08B37/0057 ,  G01N33/5055

Abstract: A complete remedy for AIDS is difficult to obtain. As such, a useful process was designed to search for an anti-HIVi agent that has an immuno response modification activity capable of releasing immuno suppression, activating killer cells to destroy persistent infection cells, elevating antibody titer to activate ADCC activity, and vice versa. The process consists of 4 elements: guinea pig or mouse peritoneal derived adherent macrophages/monocytes as effector cells; cyclophosphamide as an immuno suppressor; chicken RBC as target cells; and the anti-HIVi agent candidate to be examined. Immunovir and components were isolated from Pyrus serotina Rehder and other species of Rosaceae by column chromatography. Another useful process is the comparison of fluorescent antibody (FA) titer patterns among one round, two round, and non-medicated infected monkeys. The results of such processes can show that the anti-HIVi agent, such as these immunovirs, are noble candidates for the complete remedy of AIDS.

Abstract translation: 艾滋病的完整补救办法很难获得。 因此，设计了一种有用的方法来寻找具有免疫应答修饰活性的抗HIV剂，其能够释放免疫抑制，激活杀伤细胞以破坏持续感染细胞，提高抗体滴度以激活ADCC活性，反之亦然。 该过程由4个元素组成：豚鼠或小鼠腹膜来源的贴壁巨噬细胞/单核细胞作为效应细胞; 环磷酰胺作为免疫抑制剂; 鸡红细胞作为靶细胞; 和要检查的抗HIVi试剂候选物。 通过柱层析从Pyrus serotina Rehder和其他蔷薇科物种分离免疫病毒和组分。 另一个有用的过程是比较一轮，两轮和未加药的受感染猴子之间的荧光抗体（FA）效价模式。 这些过程的结果可以表明，抗HIVi剂，如这些免疫毒性剂，是艾滋病完全补救的高贵候选者。

公开(公告)号：WO2015031787A2

公开(公告)日：2015-03-05

申请号：PCT/US2014/053471

申请日：2014-08-29

Applicant: LONGHORN VACCINES AND DIAGNOSTICS, LLC

Inventor： FISCHER, Gerald W. ,  DAUM, Luke T. ,  SEI, Clara Jabet

IPC: A61K39/04 ,  C07K16/12 ,  A61K39/40 ,  C07K14/35 ,  G01N33/50

CPC classification number: A61K39/04 ,  A61K39/12 ,  A61K39/40 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/70 ,  C07K14/35 ,  C07K16/1289 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/31 ,  C12N2760/16134 ,  G01N33/5055

Abstract: The invention is directed to compositions and methods for generating or enhancing the immune system of a patient against infection by a pathogen, and in particular MTB. Compositions of the invention contain one or more non-naturally occurring antigens that generate an effective cellular or humoral immune response to MTB and/or antibodies that are specifically reactive to mycolic acid or to the surface of MTB. The greater activity of the immune system generated by a vaccine of the invention involve an conjugation of peptides to increase in the generation of memory T cells that provide for a greater and/or longer lived or extended response to an MTB infection. Preferably a response involves an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.

Abstract translation: 本发明涉及用于产生或增强患者的免疫系统抵抗病原体，特别是MTB感染的组合物和方法。 本发明的组合物含有一种或多种非天然存在的抗原，其对MTB和/或对分枝菌酸或MTB表面特异性反应的抗体产生有效的细胞或体液免疫应答。 由本发明的疫苗产生的免疫系统的更大的活性涉及肽的缀合以增加记忆T细胞的产生，所述记忆T细胞对MTB感染提供更大和/或更长寿命或延长的应答。 优选地，应答包括增加的抗体产生，所述抗体增强针对MTB感染的免疫性并促进增强的吞噬反应。

公开(公告)号：WO2014012933A1

公开(公告)日：2014-01-23

申请号：PCT/EP2013/065015

申请日：2013-07-16

Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Inventor： FEJER, György ,  FREUDENBERG, Marina ,  GYÓRY, Ildikó ,  GALANOS, Chris

IPC: C12N5/0786 ,  A61K35/14 ,  A61P37/00

CPC classification number: C12N5/0645 ,  C12N2501/22 ,  G01N33/5055

Abstract: The present invention relates to a method for producing self-renewing, non-transformed macrophages comprising: culturing a cell preparation obtained from an organ obtained from a mammal in culture medium to which granulocyte macrophage colony-stimulating factor (GM- CSF) has been added; thereby differentiating the cell population into self-renewing, non- transformed macrophages. The present invention further relates to macrophages obtainable by the method of the invention as well as their use in medicine or medical/pharmaceutical research. Furthermore, the present invention relates to a method of identifying a compound having a pharmacological, differentiating, proliferative or anti-proliferative, cytotoxic or transforming effect on the self-renewing, non-transformed macrophages of the invention as well as a method of identifying a compound capable of treating a disease selected from the group consisting of an inflammatory disease, infections, asthma, contact allergies as well as the side effects associated with virus vector gene-therapy.

Abstract translation: 本发明涉及一种生产自我更新的非转化巨噬细胞的方法，包括：培养从已经添加了粒细胞巨噬细胞集落刺激因子（GM-CSF）的培养基中从哺乳动物获得的器官获得的细胞制剂 ; 从而将细胞群分化为自我更新的非转化巨噬细胞。 本发明还涉及通过本发明的方法获得的巨噬细胞以及它们在医药或医药/药物研究中的应用。 此外，本发明涉及鉴定本发明的自我更新的未转化的巨噬细胞具有药理学，分化，增殖或抗增殖，细胞毒性或转化效应的化合物的方法，以及鉴定 能够治疗选自炎性疾病，感染，哮喘，接触性过敏以及与病毒载体基因治疗相关的副作用的疾病的化合物。

公开(公告)号：WO2013178931A1

公开(公告)日：2013-12-05

申请号：PCT/FR2013/051181

申请日：2013-05-28

Applicant: ROQUETTE FRERES

Inventor： DUVET, Sophie ,  HACINE-GUERBI, Héla ,  LANOS, Pierre ,  ALLAIN, Fabrice ,  CARPENTIER, Mathieu ,  DENYS, Agnès

IPC: G01N33/50 ,  G01N33/68

CPC classification number: G01N33/5055 ,  C12Q1/6897 ,  G01N33/6863 ,  G01N2333/705 ,  G01N2333/70596

Abstract: La présente invention est relative à un procédé permettant de déterminer l'impact d'une étape de production ou d'une étape de purification sur la présence ou la nature des molécules pro-inflammatoires contaminantes dans des polymères de glucose ou leurs hydrolysats en utilisant un test in vitro de réponse inflammatoire à l'aide de lignées cellulaires. Elle concerne en outre une méthode de production ou de purification optimisée de polymères de glucose ou leurs hydrolysats comprenant une analyse des molécules pro-inflammatoires contaminantes dans des polymères de glucose ou leurs hydrolysats et la sélection d'étapes deproduction ou de purification optimisée au regard de la présence et nature des molécules pro-inflammatoires contaminantes.

Abstract translation: 本发明涉及通过使用细胞系的炎症反应的体外测试来确定生产步骤或纯化步骤对葡萄糖聚合物或其水解产物中促炎性污染分子的存在或性质的影响的方法。 它还涉及生产或纯化葡萄糖聚合物或其水解产物的优化方法，其包括对葡萄糖聚合物或其水解产物中的促炎污染分子的分析，以及选择相对于存在和优化的生产或纯化步骤 促炎症污染分子的性质。

公开(公告)号：WO2013135775A1

公开(公告)日：2013-09-19

申请号：PCT/EP2013/055159

申请日：2013-03-13

Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT-BONN ,  BECTON DICKINSON AND COMPANY

Inventor： SCHULTZE, Joachim ,  MALLMANN, Michael

IPC: C12Q1/68 ,  C12N5/0786 ,  G01N33/50

CPC classification number: C12Q1/6888 ,  C12N5/0645 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/5055 ,  G01N2333/70596

Abstract: The invention is based on the finding of specific surface markers for M1-like (classically activated) and M2-like (alternatively activated) macrophages and provides for a method for the identification, characterization and isolation of M1-like and M2-like macrophages based on the abundance of said surface markers and for means for performing such method.

Abstract translation: 本发明基于M1样（经典活化）和M2样（或活化的）巨噬细胞的特异性表面标志物的发现，并提供用于鉴定，表征和分离M1样和M2样巨噬细胞的方法 对所述表面标记的丰度和用于执行这种方法的手段。

公开(公告)号：WO2012068355A2

公开(公告)日：2012-05-24

申请号：PCT/US2011/061158

申请日：2011-11-17

Applicant: TUFTS MEDICAL CENTER, INC. ,  GALPER, Jonas, B.

Inventor： GALPER, Jonas, B.

IPC: A61K35/74 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61K31/739 ,  A61P9/10

CPC classification number: A61K35/74 ,  A61K31/739 ,  A61K38/08 ,  A61K38/10 ,  A61K38/164 ,  G01N33/505 ,  G01N33/5055 ,  G01N33/6893 ,  G01N2800/329 ,  G01N2800/52

Abstract: Methods for treating aortic aneurysm, such as abdominal aortic aneurysm (AAA), by either activating TLR2 signaling or suppressing TLR4 signaling and methods for diagnosing aortic aneurysm and assessing aortic aneurysm treatment efficacy in, e.g., a laboratory animal, based on the amount of an immune cell population such as the regulatory T cell population and/or the M1 and M2 macrophage populations. Also disclosed herein are pharmaceutical compositions for use in treating aortic aneurysm, the composition comprising a TLR2 agonist, a TLR4 antagonist, or a combination thereof.

Abstract translation: 用于通过激活TLR2信号传导或抑制TLR4信号的治疗主动脉瘤，例如腹主动脉瘤（AAA）的方法以及用于诊断主动脉瘤的方法和基于实验室动物的量来评价主动脉瘤治疗功效的方法 免疫细胞群体，例如调节性T细胞群体和/或M1和M2巨噬细胞群体。 本文还公开了用于治疗主动脉瘤的药物组合物，所述组合物包含TLR2激动剂，TLR4拮抗剂或其组合。